AIM’s Latest Newsletter: The Research Edition, July 2023

Published:  
08/01/2023
Categories:  
Blog - Melanoma360
 | 
Melanoma Research
Image

This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.

This edition features:

  • Letter from AIM’s President, Sam Guild
  • Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
    By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory
  • In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
    By Kim Margolin, M.D., FACP, FASCO
  • Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
    By Alicia Rowell, Vice President, AIM at Melanoma

Recent Posts

Featured image for “Individualized Cancer Vaccine Shows Encouraging Results for Patients at High Risk for Recurrence”
Oct. 24, 2026

Individualized Cancer Vaccine Shows Encouraging Results for Patients at High Risk for Recurrence

Featured image for “Melanoma Treatment: What Happens When It’s Time for a Different Option?”
Sep. 30, 2026

Melanoma Treatment: What Happens When It’s Time for a Different Option?

Featured image for “Women in Melanoma: A New Chapter in Europe”
Aug. 31, 2026

Women in Melanoma: A New Chapter in Europe

Featured image for “The Legal & Financial Side of a Diagnosis: What No One Tells You”
Aug. 31, 2026

The Legal & Financial Side of a Diagnosis: What No One Tells You

Featured image for “Positive Phase 3 Results for Personalized mRNA Therapy in Melanoma”
Aug. 19, 2026

Positive Phase 3 Results for Personalized mRNA Therapy in Melanoma

Filter by Tag